[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100070526":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":15,"responsibleParty":26,"collaborators":7,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":7,"eligibilityCriteria":34,"healthyVolunteers":30,"sex":35,"minAge":36,"maxAge":37,"enrollmentInfo":38,"targetDuration":7,"studyType":40,"phases":41,"briefSummary":43,"conditions":44,"keywords":46,"overallStatus":48,"whyStopped":7,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":7,"leadSponsor":55,"locationsCount":57},{"fullName":5,"class":6},"Novartis","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Everolimus",[13],{"name":5,"affiliation":5,"role":14},"STUDY_DIRECTOR",[16],{"facility":5,"status":7,"city":17,"state":7,"zip":7,"country":18,"countryCode":19,"cosmosGeoPoint":20,"geoPoint":25,"contacts":7},"Basel","Switzerland","CH",{"type":21,"coordinates":22},"Point",[23,24],7.57327,47.55839,{"lat":24,"lon":23},{"type":27,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100070526","phase-4-efficacy-and-safety-of-the-switch-from-sirolimus-to-everolimus-in-stable-maintenance-renal-transplant-patients-receiving-a-calcineurin-inhibitor-free-regimen-100070526",false,"NCT00170820","Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen","A Single Arm, Prospective, Open-label, Pilot Study to Assess Effects of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen","Inclusion Criteria:\n\n* First or second renal transplantation (1 to 10 years post-transplant)\n* Treatment with sirolimus + mycophenolate mofetil + steroids + ACE inhibitor or angiotensin II receptor antagonist + statin\n\nExclusion Criteria\n\n* Treatment with a CNI or azathioprine\n* Vascular rejection or biopsy-proven acute rejection within 3 months prior to screening\n* Severe dyslipidemia Other protocol-defined inclusion \u002F exclusion criteria may apply","ALL","18 Years","75 Years",{"count":39,"type":7},20,"INTERVENTIONAL",[42],"PHASE4","The purpose of this study is to assess if a combination of everolimus, steroids, and mycophenolate mofetil is associated with a better renal function than sirolimus.",[45],"Renal Transplantation",[47],"Renal transplantation, maintenance, switch, everolimus, CNI-free","COMPLETED","2017-02-23",{"date":51,"type":52},"2017-02-27","ACTUAL",{"date":54,"type":7},"2005-02",{"name":56,"class":6},"Novartis Pharmaceuticals",1]